Hualan Biological Vaccine - Public Comps and Valuation Multiples

Hualan Biological Vaccine Overview

About Hualan Biological Vaccine

Hualan Biological Vaccine Inc is engaged in Research, development, production and sales of human vaccines.

Founded

2005

HQ

Employees

n/a

Website

hualanbacterin.com

Sectors

Vaccines & Immunotherapies
BioTech

Financials

Last FY Revenue $162M

Last FY EBITDA $51.8M

EV

$1.6B

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Hualan Biological Vaccine Financials

See Hualan Biological Vaccine valuation multiples based on analyst estimates

Hualan Biological Vaccine P&L

In the most recent fiscal year, Hualan Biological Vaccine reported revenue of $162M and EBITDA of $51.8M.

Hualan Biological Vaccine expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Hualan Biological Vaccine valuation multiples based on analyst estimates

	NTM	Last FY	FY 2026	FY 2027	FY 2028
Revenue	XXX	$162M	XXX	XXX	XXX
Gross Profit	XXX	$131M	XXX	XXX	XXX
Gross Margin	XXX	81%	XXX	XXX	XXX
EBITDA	XXX	$51.8M	XXX	XXX	XXX
EBITDA Margin	XXX	32%	XXX	XXX	XXX
EBIT	XXX	$24.7M	XXX	XXX	XXX
EBIT Margin	XXX	15%	XXX	XXX	XXX
Net Profit	XXX	$29.5M	XXX	XXX	XXX
Net Margin	XXX	18%	XXX	XXX	XXX
Net Debt	XXX	n/a	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for Hualan Biological Vaccine including revenue, profitability, and margin analysis across different time periods. In the most recent fiscal year, Hualan Biological Vaccine achieved $162M in revenue and $51.8M in EBITDA.
Financial Metric	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2026)	Next Fiscal Year (2027)	Two Years Forward (2028)
Total Revenue	Analyst estimates available to subscribers	$162M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	Analyst estimates available to subscribers	$131M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	Analyst estimates available to subscribers	81.2% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	Analyst estimates available to subscribers	$51.8M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	Analyst estimates available to subscribers	32.0% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	Analyst estimates available to subscribers	$24.7M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	Analyst estimates available to subscribers	15.3% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	Analyst estimates available to subscribers	$29.5M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	Analyst estimates available to subscribers	18.2% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	n/a	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for Hualan Biological Vaccine

This financial data table provides comprehensive performance metrics for Hualan Biological Vaccine, a company based in China. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Fiscal Year Performance

In the most recent fiscal year, Hualan Biological Vaccine reported $162M in total revenue.
Fiscal year EBITDA was $51.8M.
The company maintained a gross profit margin of 81.2% in the most recent fiscal year.
EBITDA margin for the fiscal year was 32.0%.
Net profit margin reached 18.2% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for Hualan Biological Vaccine. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

Hualan Biological Vaccine Stock Performance

Hualan Biological Vaccine has current market cap of CNY 13.2B (or $1.9B), and EV of CNY 11.2B (or $1.6B).

Market Cap Evolution

Hualan Biological Vaccine Stock Data

As of January 30, 2026, Hualan Biological Vaccine's stock price is CNY 22 (or $3).

See Hualan Biological Vaccine trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$1.6B	$1.9B	XXX	XXX	XXX	XXX	n/a

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Hualan Biological Vaccine Valuation Multiples

Hualan Biological Vaccine's trades at 9.9x EV/Revenue multiple, and 30.9x EV/EBITDA.

See valuation multiples for Hualan Biological Vaccine and 15K+ public comps

Hualan Biological Vaccine Financial Valuation Multiples

As of January 30, 2026, Hualan Biological Vaccine has market cap of $1.9B and EV of $1.6B.

Equity research analysts estimate Hualan Biological Vaccine's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Hualan Biological Vaccine's P/E ratio is not available.

	LTM	NTM	Last FY	FY 2026	FY 2027	FY 2028
Market cap (current)	$1.9B	XXX	$1.9B	XXX	XXX	XXX
EV (current)	$1.6B	XXX	$1.6B	XXX	XXX	XXX
EV/Revenue	n/a	XXX	9.9x	XXX	XXX	XXX
EV/EBITDA	n/a	XXX	30.9x	XXX	XXX	XXX
EV/EBIT	n/a	XXX	64.8x	XXX	XXX	XXX
EV/Gross Profit	n/a	XXX	n/a	XXX	XXX	XXX
P/E	n/a	XXX	64.2x	XXX	XXX	XXX
EV/FCF	n/a	XXX	26.8x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Hualan Biological Vaccine Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Hualan Biological Vaccine Margins & Growth Rates

Hualan Biological Vaccine's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.

Hualan Biological Vaccine's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Hualan Biological Vaccine's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Hualan Biological Vaccine and other 15K+ public comps

Hualan Biological Vaccine Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2026	FY 2027	FY 2028
Revenue Growth	n/a	XXX	n/a	XXX	XXX	XXX
EBITDA Margin	n/a	XXX	n/a	XXX	XXX	XXX
EBITDA Growth	n/a	XXX	n/a	XXX	XXX	XXX
Rule of 40	n/a	XXX	n/a	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	n/a	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	n/a	XXX	XXX	XXX
Opex per Employee	XXX	XXX	n/a	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	44%	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	14%	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	66%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial